PTLA Portola Pharmaceuticals, Inc.

+1.41  (4.66%)
Previous Close 30.27
Open 30.27
Price To book 7.24
Market Cap 1.79B
Shares 56,543,000
Volume 1,464,083
Short Ratio 5.21
Av. Daily Volume 1,160,670

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
Phase 2 enrolment commenced May 2016. Continues to enroll as of November 2016.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
CRL August 17 2016
Andexanet alfa
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
  2. Portola Pharmaceuticals Inc (PTLA) Just Scored Twice In Quick Succession
  3. Portola Pharmaceuticals Inks $150M Royalty Deal
  4. FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
  5. Portola, HealthCare Royalty Partners Ink $150 Million Deal
  6. Premarket Biotech Movers: Portola, Esperion, Medicines
  7. PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
  8. Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
  9. 3 Biotech Stocks I'd Buy Right Now
  10. Why Portola Pharmaceuticals Crashed 56.4% In 2016
  11. 3 Little-Known Pharmaceutical Companies to Put on Your Radar
  12. 2 Top Stocks in Biotech
  13. My Worst Predictions for Biotech in 2016
  14. Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
  15. Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
  16. Portola Pharma upgraded by Citigroup
  17. Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
  18. Why Portola Pharmaceuticals Inc Stock Surged Higher Today
  19. Why Portola Pharmaceuticals, Caesars Entertainment, and Cal-Maine Foods Jumped Today